TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17666497

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone (25 mg or 50 mg every 14 days)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Oral olanzapine (5-20 mg/day)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Long-acting risperidone
Number of subjects: 377

Group type: COMPARATOR
Intervention: Oral olanzapine
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 377
Study: 15502112

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (bud/form) maintenance + relief (80/4.5 microg twice a day with 80/4.5 microg as-needed)
Number of subjects: 2760

Group type: COMPARATOR
Intervention: Budesonide/formoterol (bud/form) + SABA (terbutaline 0.4 mg)
Number of subjects: 2760

Group type: COMPARATOR
Intervention: Budesonide (bud) + SABA (terbutaline 0.4 mg)
Number of subjects: 2760

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (bud/form) maintenance + relief
Number of subjects: 2760
Study: 11925466

Group type: EXPERIMENTAL
Intervention: Refined olive oil (rich in monounsaturated fatty acids, n = 18)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Rapeseed oil (rich in MUFA and (n‐3)‐polyunsaturated fatty acids, n = 18)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Sunflower oil (rich in (n‐6)‐PUFA, n = 20)
Number of subjects: 56
Study: 9585655

Group type: EXPERIMENTAL
Intervention: Amitriptyline (AMI), flexible dose, final dose 173.1 mg/day ± 56.3 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 8596757

Group type: EXPERIMENTAL
Intervention: Intensive insulin treatment
Number of subjects: 30
Study: 2503346

Group type: EXPERIMENTAL
Intervention: Methadone treatment
Number of subjects: 174

Group type: COMPARATOR
Intervention: Control group (no methadone)
Number of subjects: 174
Study: 779502

Group type: EXPERIMENTAL
Intervention: Clofazimine 200 mg daily 6 days per week (regimen 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofazimine 100 mg three times weekly (regimen 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofazimine 300 mg weekly (regimen 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofazimine 600 mg every other week (regimen 4)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clofazimine 600 mg on 2 consecutive days every 4 weeks (regimen 5)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clofazimine 200 mg daily 6 days per week (regimen 6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dapsone, starting with a small dosage and increasing to 100 mg daily 6 days per week (regimen 7)
Number of subjects: 0
Study: 29744804

Group type: EXPERIMENTAL
Intervention: Controlled antipsychotic treatment for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Simple response conflict task
Number of subjects: 33

Group type: COMPARATOR
Intervention: Simple fMRI task
Number of subjects: 33
Study: 30376810

Group type: EXPERIMENTAL
Intervention: Programmed Intermittent Epidural Bolus (PIEB) 6 mL/h of ropivacaine 0.2%
Number of subjects: 84

Group type: COMPARATOR
Intervention: Continuous Epidural Infusion (CEI) 6 mL/h of ropivacaine 0.2%
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both groups (PIEB and CEI)
Number of subjects: 84
Study: 26772985

Group type: EXPERIMENTAL
Intervention: Early prophylactic levothyroxine (LT4) treatment
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard follow-up
Number of subjects: 94
Study: 25444083

Group type: EXPERIMENTAL
Intervention: Rotigotine transdermal system (up to 16 mg/24 h)
Number of subjects: 596
Study: 22095403

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided injection
Number of subjects: 44

Group type: COMPARATOR
Intervention: Manual (non-US-guided) injection
Number of subjects: 44

Group type: COMPARATOR
Intervention: Comparison of US-guided vs Manual injection
Number of subjects: 44
Study: 20809930

Group type: EXPERIMENTAL
Intervention: 4-week preconditioning program with walking and hopping exercises
Number of subjects: 0

Group type: COMPARATOR
Intervention: 9-week training program (Control group)
Number of subjects: 0
Study: 17679652

Group type: EXPERIMENTAL
Intervention: Diabetes at baseline
Number of subjects: 15245

Group type: EXPERIMENTAL
Intervention: New-onset diabetes
Number of subjects: 15245

Group type: COMPARATOR
Intervention: No diabetes
Number of subjects: 15245
Study: 16252739

Group type: EXPERIMENTAL
Intervention: Injection pressure of 30 s/mL
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Injection pressure of 160 s/mL
Number of subjects: 28
Study: 12014163

Group type: EXPERIMENTAL
Intervention: 1% titanium tetrafluoride (0.32 MF) for 1 minute
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Duraphat (2.26% F) for 4 minutes
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Elmex (1.25% F) for 4 minutes
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no solution applied)
Number of subjects: 40
Study: 10215284

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 59
Study: 8582499

Group type: EXPERIMENTAL
Intervention: Filgrastim (granulocyte colony stimulating factor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 0
Study: 2198308

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 635480

Group type: EXPERIMENTAL
Intervention: 0.02% chlorhexidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.25% silver nitrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.25% acetic acid
Number of subjects: 0
Study: 31769596

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel treatment
Number of subjects: 100
Study: 31134827

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO) in addition to conventional treatment, 5 days per week, 60 min each, 100% oxygen at 2 standard atmospheric pressures for 12 weeks.
Number of subjects: 158

Group type: COMPARATOR
Intervention: Conventional treatment (Control group).
Number of subjects: 158
Study: 28186838

Group type: EXPERIMENTAL
Intervention: Group <70 (mean dose <70.2Gy)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Group >70 (mean dose >70.2Gy)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Group >70
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Group <70
Number of subjects: 181
Study: 26404912

Group type: EXPERIMENTAL
Intervention: Tiotropium 1.25 µg + Olodaterol 5 µg
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 µg + Olodaterol 5 µg
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg + Olodaterol 5 µg
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Tiotropium 1.25 µg + Olodaterol 10 µg
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 µg + Olodaterol 10 µg
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Tiotropium 5 µg + Olodaterol 10 µg
Number of subjects: 233
Study: 23407406

Group type: EXPERIMENTAL
Intervention: KIVA
Number of subjects: 168

Group type: COMPARATOR
Intervention: BK
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Both KIVA and BK
Number of subjects: 168
Study: 21495198

Group type: EXPERIMENTAL
Intervention: 20 mg of hyoscine-N-butyl bromide (HBB) rectal suppository
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo suppository
Number of subjects: 130
Study: 19054777

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone application preceding standard gonadotrophin ovarian stimulation
Number of subjects: 62

Group type: COMPARATOR
Intervention: High-dose gonadotrophin with minidose GnRH agonist protocol
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone application
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone application (normal basal FSH levels)
Number of subjects: 62

Group type: COMPARATOR
Intervention: High-dose gonadotrophin with minidose GnRH agonist protocol (normal basal FSH levels)
Number of subjects: 62
Study: 17613264

Group type: EXPERIMENTAL
Intervention: NO-collecting solutions with NO-scavenging compounds (hemoglobin or 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide) placed inside tubing attached to skin for 20 min
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite pretreatment of skin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control areas (non-meridian)
Number of subjects: 50
Study: 15598977

Group type: EXPERIMENTAL
Intervention: IM862 (5 mg intranasally every other day)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: IM862
Number of subjects: 202
Study: 12104081

Group type: EXPERIMENTAL
Intervention: Athletes before competition
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Athletes after competition
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Athletes before exercise
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Athletes after exercise
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sedentary individuals
Number of subjects: 60
Study: 9617985

Group type: EXPERIMENTAL
Intervention: Naltrexone 200 mg/day for 3 weeks
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Naltrexone (single-blind) after placebo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Naltrexone (subsequent treatment)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7925218

Group type: EXPERIMENTAL
Intervention: Rocuronium 0.6 mg kg‐1 for intubation followed by an infusion controlled by closed‐loop feedback at 90% block.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Isoflurane and N2O
Number of subjects: 60
Study: 2701811

Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized Phase II trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phase III designs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inappropriate sequential analysis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: General methods for valid calculation of confidence limits
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Factorial designs
Number of subjects: 0
Study: 1098524

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 60 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Triprolidine 2.5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combination of pseudoephedrine and triprolidine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31229641

Group type: EXPERIMENTAL
Intervention: r-ATG (4.5 mg/kg)
Number of subjects: 357
Study: 28965280

Group type: EXPERIMENTAL
Intervention: Acetazolamide (oral, once daily, dose-adjusted to body weight)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 25962410

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg/day
Number of subjects: 123
Study: 23883378

Group type: EXPERIMENTAL
Intervention: Riociguat 2.5 mg-maximum group
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 443
Study: 21816062

Group type: EXPERIMENTAL
Intervention: LAM plus ADV
Number of subjects: 53

Group type: COMPARATOR
Intervention: LAM alone
Number of subjects: 53
Study: 19565156

Group type: EXPERIMENTAL
Intervention: Neck stabilization exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physical therapy agents + isometric and stretching exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Physical therapy agents
Number of subjects: 60
Study: 18958903

Group type: EXPERIMENTAL
Intervention: Postoperative drainage
Number of subjects: 100

Group type: COMPARATOR
Intervention: No drains (Control)
Number of subjects: 100
Study: 14666399

Group type: EXPERIMENTAL
Intervention: Paroxetine (40 mg daily)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11383810

Group type: EXPERIMENTAL
Intervention: Synthetic surgical lung sealant (SLS) applied intraoperatively
Number of subjects: 124

Group type: COMPARATOR
Intervention: Standard closure without SLS
Number of subjects: 124
Study: 9209013

Group type: EXPERIMENTAL
Intervention: Dietary changes towards patterns associated with lower risk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Beta-carotene and other compounds
Number of subjects: 0
Study: 8480900

Group type: EXPERIMENTAL
Intervention: 0.6% isoflurane/66% nitrous oxide anesthesia during surgical stimulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.6% isoflurane/66% nitrous oxide anesthesia without surgical stimulation
Number of subjects: 20
Study: 3501252

Group type: EXPERIMENTAL
Intervention: Propofol (2 mg/kg body weight)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Midazolam (0.15 mg/kg)
Number of subjects: 34
Study: 28899827

Group type: EXPERIMENTAL
Intervention: Clitoral vacuum suction device (CVSD)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Vibratory stimulation (V)
Number of subjects: 31
Study: 26331782

Group type: EXPERIMENTAL
Intervention: Drug-coated scoring balloon (SB)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Uncoated scoring balloon (SB)
Number of subjects: 61
Study: 24232511

Group type: EXPERIMENTAL
Intervention: Harmonic dissection
Number of subjects: 152

Group type: COMPARATOR
Intervention: Electrocautery
Number of subjects: 152
Study: 23543483

Group type: EXPERIMENTAL
Intervention: Piribedil up to 300 mg per day (n = 19)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Piribedil
Number of subjects: 37
Study: 20065252

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (RS) with 20 or 24 Gy 50% isodose
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Stereotactic radiosurgery (RS)
Number of subjects: 30
Study: 18457471

Group type: EXPERIMENTAL
Intervention: Alfimeprase (0.3 mg/kg)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study: 17283928

Group type: EXPERIMENTAL
Intervention: Luminance contrasts inherent in the disk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Luminance contrasts between adjoining areas of the background outside the disk
Number of subjects: 0
Study: 12884458

Group type: EXPERIMENTAL
Intervention: Adalimumab (HUMIRA)
Number of subjects: 0
Study: 10970993

Group type: EXPERIMENTAL
Intervention: Dietary beta-carotene supplementation (60 mg daily for 3 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (normoglycemic subjects)
Number of subjects: 20
Study: 8978957

Group type: EXPERIMENTAL
Intervention: D-Penicillamine (DPA)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study: 1361081

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Piportil
Number of subjects: 48
Study: 3881176

Group type: EXPERIMENTAL
Intervention: Doxorubicin and lomustine (DC)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cyclophosphamide and 5‐FU (CF)
Number of subjects: 51
Study: 30221595

Group type: EXPERIMENTAL
Intervention: 100 mg of enteric-coated aspirin
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study: 27654263

Group type: EXPERIMENTAL
Intervention: FIGO IVB AWM only (n = 86)
Number of subjects: 634

Group type: COMPARATOR
Intervention: FIGO IIIC (n = 308)
Number of subjects: 634

Group type: COMPARATOR
Intervention: FIGO IV others (n = 240)
Number of subjects: 634

Group type: COMPARATOR
Intervention: FIGO IIIC
Number of subjects: 634
Study: 25758385

Group type: EXPERIMENTAL
Intervention: Play-reading intervention
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard medical lecture
Number of subjects: 129
Study: 22924071

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide/formoterol
Number of subjects: 22

Group type: COMPARATOR
Intervention: Inhaled fluticasone/salmeterol
Number of subjects: 22
Study: 21114387

Group type: EXPERIMENTAL
Intervention: Echinocandins
Number of subjects: 1169

Group type: COMPARATOR
Intervention: Nonechinocandins (comparator drug)
Number of subjects: 1169
Study: 18534669

Group type: COMPARATOR
Intervention: Radiotherapy (56 Gy) only (Group A, n=72)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with three courses of cisplatin (50 mg/m(2)), epirubicin (60 mg/m(2)), and cyclophosphamide (500 mg/m(2)) (Group B, n=84)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with three courses of cisplatin, epirubicin, and cyclophosphamide (Group B, n=84)
Number of subjects: 156
Study: 15757614

Group type: EXPERIMENTAL
Intervention: Triiodothyronine (T3) supplementation
Number of subjects: 0
Study: 13130389

Group type: EXPERIMENTAL
Intervention: EGb 761 (120 mg)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study: 10535718

Group type: COMPARATOR
Intervention: enalapril 10 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: amlodipine 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: carvedilol 25 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: celiprolol 200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: celiprolol 200 mg daily
Number of subjects: 10
Study: 8671386

Group type: EXPERIMENTAL
Intervention: LA and NETA (n = 47)
Number of subjects: 105

Group type: COMPARATOR
Intervention: LA alone (n = 58)
Number of subjects: 105
Study: 1745340

Group type: EXPERIMENTAL
Intervention: Prednisone 0.75 mg/kg/d
Number of subjects: 93

Group type: COMPARATOR
Intervention: Natural history controls
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Prednisone (varied dosages from 0.15 mg/kg to 0.75 mg/kg)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Prednisone therapy
Number of subjects: 93
Study: 6136489

Group type: EXPERIMENTAL
Intervention: lopirazepam (tranquillizing agent)
Number of subjects: 72

Group type: COMPARATOR
Intervention: placebo treatment
Number of subjects: 72
Study: 30760169

Group type: EXPERIMENTAL
Intervention: Intravenous alteplase treatment
Number of subjects: 601
Study: 28392365

Group type: EXPERIMENTAL
Intervention: EUS-guided ERCP without fluoroscopy (EGEWF)
Number of subjects: 114

Group type: COMPARATOR
Intervention: ERCP (standard method)
Number of subjects: 114
Study: 25529590

Group type: EXPERIMENTAL
Intervention: Modified WAIS-IV Symbol Search subtest (responding with 'x')
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Modified WAIS-IV Block Design (all items with red surfaces facing up)
Number of subjects: 50
Study: 23228119

Group type: EXPERIMENTAL
Intervention: 0.025% capsaicin gel
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 21823969

Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ combination therapy administered at bedtime
Number of subjects: 204

Group type: COMPARATOR
Intervention: Valsartan/HCTZ combination therapy administered upon awakening
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Both treatment-time groups (bedtime and upon awakening)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Bedtime combination treatment
Number of subjects: 204
Study: 19152452

Group type: EXPERIMENTAL
Intervention: Immunonutrition (arginine, fatty acids, nucleotides)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Normal nutrition
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard enteral nutrition
Number of subjects: 42
Study: 17208952

Group type: EXPERIMENTAL
Intervention: Intensive prevention programme (including physical exercise in small groups, psychosocial group activities, lectures, and home exercises)
Number of subjects: 591

Group type: COMPARATOR
Intervention: Counselling group (control group)
Number of subjects: 591
Study: 15526557

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone (200 mg/daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral progesterone (200 mg/daily)
Number of subjects: 24
Study: 12784831

Group type: EXPERIMENTAL
Intervention: Cusp catastrophe model
Number of subjects: 94

Group type: COMPARATOR
Intervention: Traditional linear models
Number of subjects: 94
Study: 9880623

Group type: EXPERIMENTAL
Intervention: Expert interpretation of sonographic films with a grading scale of severity for nephrocalcinosis
Number of subjects: 30
Study: 7754079

Group type: EXPERIMENTAL
Intervention: Collaborative recall in pairs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual recall
Number of subjects: 0
Study: 2272708

Group type: EXPERIMENTAL
Intervention: Calcium gluconate therapy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combined administration of calcium and nifedipine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 41
Study: 7419561

Group type: EXPERIMENTAL
Intervention: Dipyridamole and acetylsalicylic acid (ASA)
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Dipyridamole alone
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) alone
Number of subjects: 389

Group type: COMPARATOR
Intervention: Control group without antithrombotic therapy
Number of subjects: 389
Study: 31779683

Group type: EXPERIMENTAL
Intervention: Adapted Mindfulness-Based Childbirth and Parenting (MBCP) program + treatment as usual (TAU)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) only
Number of subjects: 122
Study: 28953037

Group type: EXPERIMENTAL
Intervention: Dried Blood Spots (DBS)
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: DBS-predicted plasma values
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Intensive DBS sampling
Number of subjects: 630
Study: 26523692

Group type: EXPERIMENTAL
Intervention: High-valued pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low-valued pairs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normatively effective encoding strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluid intelligence
Number of subjects: 0
Study: 24253250

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (10 mg/daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20881400

Group type: EXPERIMENTAL
Intervention: Simultaneous treatment for quitting both alcohol and tobacco
Number of subjects: 92

Group type: COMPARATOR
Intervention: Delayed treatment (help to quit smoking after 6 months)
Number of subjects: 92
Study: 19016404

Group type: EXPERIMENTAL
Intervention: SHR‐5 extract (576 mg extract/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (four tablets daily)
Number of subjects: 60
Study: 17589283

Group type: EXPERIMENTAL
Intervention: Heart-to-Heart (HTH) walking program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 46